Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.

Vaia Florou,Charalampos S Floudas,Asaf Maoz,Abdul Rafeh Naqash,Carter Norton,Aik Choon Tan,Ethan S Sokol,Garrett Frampton,Heloisa P Soares,Sonam Puri,Umang Swami,Breelyn Wilky,Peter Hosein,Jonathan Trent,Gilberto de Lima Lopes,Wungki Park,Ignacio Garrido-Laguna

Journal for immunotherapy of cancer（2023）

引用 0|浏览34

暂无评分

摘要

FSs are found in 47% of patients with MSS/TMB-L solid tumors in a pan-cancer cohort. FS may complement TMB in predicting immunotherapy responses, particularly for tumors with low TMB.

查看译文

关键词

tumor biomarkers, immune checkpoint inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要